{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:49:30Z","timestamp":1794473370038,"version":"4.9.1"},"reference-count":11,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Optimal antithrombotic therapy after percutaneous left atrial appendage occlusion (LAAO) is not well established as no randomized evaluation has been performed to date.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare the efficacy and safety of low-dose direct oral anticoagulation (low-dose DOAC) vs dual antiplatelet therapy (DAPT) for 3 months after LAAO.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>The ADALA (Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion) study was an investigator-initiated, multicenter, prospective, open-label, randomized clinical trial enrolling participants from June 12, 2019, to August 28, 2022 from 3 European sites. Patients who underwent successful LAAO were randomly assigned 1:1 to low-dose DOAC vs DAPT for 3 months after LAAO. The study was prematurely terminated when only 60% of the estimated sample size had been included due to lower recruitment rate than anticipated due to the COVID-19 pandemic.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>The low-dose DOAC group received apixaban, 2.5 mg every 12 hours, and the DAPT group received aspirin, 100 mg per day,\u2009plus\u2009clopidogrel, 75 mg per day, for the first 3 months after LAAO.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary end point was a composite of safety (major bleeding) and efficacy (thromboembolic events including stroke, systemic embolism, and device-related thrombosis [DRT]) within the first 3 months after successful LAAO. Secondary end points included individual components of the primary outcome and all-bleeding events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 90 patients (mean [SD] age, 76.6\u2009[8.1] years; 60 male [66.7%]; mean [SD] CHADS-VASc score, 4.0\u2009[1.5]) were included in the analysis (44 and 46 patients in the low-dose DOAC and DAPT groups, respectively). A total of 53 patients (58.8%) presented with previous major bleeding events (60 gastrointestinal [66.7%] and 16 intracranial [17.8%]). At 3 months, low-dose DOAC was associated with a reduction of the primary end point compared with DAPT (2 [4.5%] vs 10 [21.7%]; hazard ratio, 0.19; 95% CI, 0.04-0.88; <jats:italic>P<\/jats:italic>\u2009=\u2009.02). Patients in the low-dose DOAC group exhibited a lower rate of DRT (0% vs 6 [8.7%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.04) and tended to have a lower incidence of major bleeding events (2 [4.6%] vs 6 [13.0%]; <jats:italic>P<\/jats:italic>\u2009=\u2009.17), with no differences in thromboembolic events such as stroke and systemic embolism between groups (none in the overall population).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This was a small, randomized clinical trial comparing different antithrombotic strategies after LAAO. Results show that use of low-dose DOAC for 3 months after LAAO was associated with a better balance between efficacy and safety compared with DAPT. However, the results of the study should be interpreted with caution due to the limited sample size and will need to be confirmed in future larger randomized trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05632445\">NCT05632445<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2024.2335","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T15:01:23Z","timestamp":1723042883000},"page":"922","source":"Crossref","is-referenced-by-count":79,"title":["Low-Dose Direct Oral Anticoagulation vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion"],"prefix":"10.1001","volume":"9","author":[{"given":"Xavier","family":"Freixa","sequence":"first","affiliation":[{"name":"Department of Cardiology, Institut Cardiovascular, IDIBAPS, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Cruz-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario of Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Cepas-Guill\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institut Cardiovascular, IDIBAPS, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavi","family":"Mill\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitari de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ant\u00fanez-Mui\u00f1os","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institut Cardiovascular, IDIBAPS, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Flores-Umanzor","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institut Cardiovascular, IDIBAPS, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Asmarats","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitari de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ander","family":"Regueiro","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institut Cardiovascular, IDIBAPS, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"L\u00f3pez-Tejero","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institut Cardiovascular, IDIBAPS, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hion Pedro","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitari de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sanchis","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institut Cardiovascular, IDIBAPS, Hospital Clinic of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Rod\u00e9s-Cabau","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institut Cardiovascular, IDIBAPS, Hospital Clinic of Barcelona, Barcelona, Spain"},{"name":"Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dabit","family":"Arzamendi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitari de la Santa Creu i Sant Pau, IIB Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"hbr240008r1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.122.012812","article-title":"Antithrombotic management after left atrial appendage closure: current evidence and future perspectives.","volume":"16","author":"Mesnier","year":"2023","journal-title":"Circ Cardiovasc Interv"},{"issue":"21","key":"hbr240008r2","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/j.jcin.2021.07.031","article-title":"Half-dose direct oral anticoagulation vs standard antithrombotic therapy after left atrial appendage occlusion.","volume":"14","author":"Della Rocca","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"hbr240008r3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.119.008481","article-title":"Reduced rivaroxaban dose vs dual antiplatelet therapy after left atrial appendage closure: ADRIFT a randomized pilot study.","volume":"13","author":"Duthoit","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"issue":"18","key":"hbr240008r4","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jacc.2023.08.010","article-title":"Network meta-analysis of initial antithrombotic regimens after left atrial appendage occlusion.","volume":"82","author":"Carvalho","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"hbr240008r5","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s10840-020-00884-x","article-title":"Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban (ADALA study).","volume":"59","author":"Flores-Umanzor","year":"2020","journal-title":"J Interv Card Electrophysiol"},{"issue":"11","key":"hbr240008r6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/jcdd8110142","article-title":"Low dose of direct oral anticoagulants after left atrial appendage occlusion.","volume":"8","author":"Cepas-Guillen","year":"2021","journal-title":"J Cardiovasc Dev Dis"},{"issue":"12","key":"hbr240008r7","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.jacep.2018.09.007","article-title":"Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion: a meta-analysis.","volume":"4","author":"Alkhouli","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"issue":"2","key":"hbr240008r8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.rec.2012.04.017","article-title":"Immediate and 1-year results in 35 consecutive patients after closure of left atrial appendage with the Amplatzer cardiac plug.","volume":"66","author":"L\u00f3pez-M\u00ednguez","year":"2013","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"1","key":"hbr240008r9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jacep.2016.05.006","article-title":"Thrombus formation after left atrial appendage occlusion with the Amplatzer amulet device.","volume":"3","author":"Sedaghat","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"issue":"19","key":"hbr240008r10","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1093\/eurheartj\/ehw454","article-title":"Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis.","volume":"38","author":"Halvorsen","year":"2017","journal-title":"Eur Heart J"},{"issue":"8","key":"hbr240008r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.20064","article-title":"Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding.","volume":"4","author":"Lip","year":"2021","journal-title":"JAMA Netw Open"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2822108\/jamacardiology_freixa_2024_br_240008_1727109893.24848.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:26:06Z","timestamp":1728487566000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2822108"}},"subtitle":["The ADALA Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2024.2335","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}